FDA & Regulatory:
Glucommander™ is FDA cleared (as a Class II medical device) for insulin dosing decision support.
Glytec’s eGMS® is proven to:
- Reduce Cost of Care
- Reduce Readmissions
- Reduce Length of Stay
- Save Clinicians Time
- Reduce Hypoglycemia
- Reduce CABG Surgery Cost, Complications, and Resources
- Successfully Convert from Sliding Scale to Basal Bolus Insulin
- Reduce Point-of-Care Blood Glucose Tests
- Reduce Admissions for Diabetic Ketoacidosis
- Reduce Time to Target Blood Glucose
- Reduce Outpatient A1C
Provides specific, personaized dosing recommendations directly to care givers and health care providers
Platforms & Modalitiy:
Security & Privacy:
Cost & Payment:
No cost to consumer, hospital purchases software. Patient cannot use on their own.
Glytec’s Glucommander™ is purpose built to overcome therapeutic inertia and drive the adoption of basal-bolus insulin therapy among providers by delivering evidence-based decision support at the point of care. Our proprietary algorithms do the heavy lifting, responding to each patient’s unique circumstances by computing when and by how much their insulin dose should be adjusted and creating personalized dosing recommendations for providers. Our technology has been implemented at nearly 300 hospitals and has been repeatedly proven to increase patient safety, decrease length of stay, reduce readmissions and drive down the overall cost of care. Glytec’s eGMS also enables detailed reporting of glycemic management metrics like incidence of hyperglycemia and hypoglycemia, time to target, patient utilization, blood glucose ranges and more.